Who Supplies Nystatin to India from SENEGAL

Importing finished pharmaceutical formulations containing Nystatin into India requires compliance with the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The Central Drugs Standard Control Organization (CDSCO) mandates that both the drug and the manufacturing site be registered. For drugs classified as "New Drugs," approval from the Drugs Controller General of India (DCGI) is necessary before importation. The registration process involves submitting an application to the Licensing Authority under the Act, which is the DCGI at CDSCO. The timeline for import drug registration can vary, but it typically involves submission of necessary documents, evaluation, and approval processes. Specific requirements for Nystatin formulations under HS Code 30049029 include providing detailed product information, manufacturing details, and compliance with Indian pharmacopoeia standards.

Imported pharmaceutical formulations containing Nystatin must undergo quality testing at CDSCO-approved laboratories. Batch-wise testing is required, with each batch accompanied by a Certificate of Analysis (CoA) confirming compliance with Indian Pharmacopoeia standards. Stability data, particularly for ICH Zone IV conditions, must be provided to demonstrate the product's stability in India's climate. Port inspection by customs drug inspectors is mandatory to ensure compliance with regulatory standards. The process includes sample collection, testing, and certification before the product is cleared for distribution. If a batch fails quality testing, it may be rejected, leading to potential delays and additional costs.

Between 2024 and 2026, the CDSCO has implemented regulatory updates affecting the import of pharmaceutical formulations, including Nystatin. The Production Linked Incentive (PLI) scheme has been introduced to encourage domestic manufacturing, potentially impacting the volume of finished formulation imports. Bilateral agreements between India and Senegal may influence import policies, including mutual recognition of Good Manufacturing Practices (GMP) and streamlined import procedures. These developments aim to balance the promotion of domestic industry with the need for imported pharmaceutical products.

India imports finished Nystatin formulations to meet domestic demand for this antifungal agent. The need arises due to factors such as the availability of patented or branded formulations, specific dosage forms not produced locally, and the capacity of domestic manufacturers to meet the market requirements. The market size for Nystatin formulations in India is substantial, driven by the prevalence of fungal infections and the demand for effective treatments.

The import duty structure for Nystatin formulations under HS Code 30049029 includes a Basic Customs Duty (BCD) of 10%, a Social Welfare Surcharge (SWS) of 10% on the BCD, and an Integrated Goods and Services Tax (IGST) of 12%. There are no additional duties specified for this product. Exemption notifications may apply under specific circumstances, such as for products covered under Free Trade Agreements (FTAs) or other bilateral agreements. The total landed duty percentage combines these components, affecting the final cost of imported goods.

India sources finished Nystatin formulations from Senegal due to factors such as the availability of patented formulations, specialized dosage forms, and competitive pricing. Senegal's share in India's Nystatin import market is relatively small compared to other suppliers like China, Germany, and the United States. However, Senegal's unique advantages, such as specific formulations not produced elsewhere, contribute to its position as a competitive source.

India imports Nystatin formulations from Senegal due to the availability of specific formulations not produced domestically, competitive pricing, and the quality standards maintained by Senegalese manufacturers. These factors make Senegal a strategic source for certain Nystatin formulations required in the Indian market.

Compared to other origins like China, the European Union, and the United States, Senegal offers competitive pricing and unique formulations. While other suppliers may have larger market shares, Senegal's niche offerings and quality compliance provide a unique advantage for Indian importers seeking specific Nystatin formulations.

Potential risks for Indian importers include reliance on a single source, currency fluctuations, regulatory changes in Senegal, quality control issues, and shipping disruptions. Past shortages have not been reported, but maintaining a diversified supplier base and robust risk management strategies are advisable to mitigate potential disruptions.

1. 1Dual-Sourcing: Engage multiple suppliers to reduce dependency on a single source.
2. 2Inventory Planning: Maintain adequate stock levels to buffer against supply chain disruptions.
3. 3Payment Terms: Negotiate favorable terms such as Letters of Credit (LC), Documents Against Acceptance (DA), or Documents Against Payment (DP).
4. 4Minimum Order Quantities (MOQs): Clarify MOQs to optimize procurement costs.
5. 5Supplier Qualification: Conduct thorough due diligence to ensure compliance with quality and regulatory standards.

1. 1DGFT Importer Exporter Code (IEC): Obtain the IEC from the Directorate General of Foreign Trade.
2. 2CDSCO Registration: Register the product with CDSCO, including submission of Form 40/41.
3. 3Drug Import License: Apply for a license under the Drugs and Cosmetics Act.
4. 4No Objection Certificate (NOC): If required, obtain an NOC from the Ministry of Health.
5. 5Customs Broker: Engage a licensed customs house agent for clearance procedures.
6. 6Advance Ruling: Seek an advance ruling for HS Code 30049029 to confirm classification and duty rates.